Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: GlobeNewswire
BOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Monday, April 7, 2025 at 8:00 a.m. ET to disclose topline results from the Pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity. Conference Call InformationRhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Monday, April 7, to discuss these clinical data. Participants may register for the conference call here. A webcast of the call will also be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at https://ir.rhythmtx.com/. The archived webcast will be available on Rhythm Pharmaceuticals’ we
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals (NASDAQ:RYTM) was given a new $141.00 price target on by analysts at Canaccord Genuity Group Inc..MarketBeat
- Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
RYTM
Earnings
- 11/4/25 - Miss
RYTM
Sec Filings
- 12/19/25 - Form 8-K
- 12/15/25 - Form 4
- 12/11/25 - Form 144
- RYTM's page on the SEC website